NEW YORK, NY / ACCESSWIRE / September 21, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies.
Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH)
Agreement Announcement: July 29, 2020
Transaction Details: "). Under the terms of the merger, Spring Bank will issue shares of common stock to the owners of F-Star, with current holders of Spring Bank common stock controlling approximately 39% of the combined company. Following the closing of the proposed merger, the combined company will be re-named F-Star Therapeutics, Inc., and trade under the ticker symbol "FSTX."
To learn more about the SBPH investigation and your rights, go to:
Immunomedics, Inc. (NASDAQ:IMMU)
Agreement Announcement: September 13, 2020
Transaction Details: Under the terms of the deal, Gilead will acquire Immunomedics for $88.00 per share in cash.
To learn more about the IMMU investigation and your rights, go to:
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)
Merger Announcement: August 19, 2020
Transaction Details: Under the terms of the merger, a subsidiary of Johnson & Johnson will acquire all outstanding shares of Momenta common stock for $52.50 per share in cash.
To learn more about the MNTA investigation and your rights, go to:
Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington, D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits, and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP